Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Triparna Sen Clear advanced filters

  • Traditionally, patients with small-cell lung cancer (SCLC), a malignancy with a dismal prognosis, have had limited treatment options. Over the past few years, advances in the molecular characterization of SCLC have revealed novel therapeutic targets. The authors of this Review summarize these findings and discuss emerging opportunities and challenges for their translation into new treatment approaches.

    • Triparna Sen
    • Nobuyuki Takahashi
    • Abdul Rafeh Naqash
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 21, P: 610-627

  • Creating accurate models of small cell lung cancer is essential to ensure the clinical relevance of results. Here, the authors create patient derived xenograft models from 33 patients and show, through multi-omics sequencing, that these models retain the primary features of the original.

    • Rebecca Caeser
    • Jacklynn V. Egger
    • Triparna Sen
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-12

  • The expression of oncogenic MYC paralogs in small cell lung cancer is mutually exclusive. In this study, the authors show that MYC, but not MYCN or MYCL, represses BCL2, resulting in cells that are uniquely sensitive to apoptosis, and find that CHK1 and AURKA inhibitors may be useful for treating these cancers.

    • Marcel A. Dammert
    • Johannes Brägelmann
    • Martin L. Sos
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-11

  • LSD1 inhibition blocks the neuroendocrine phenotype of some small cell lung cancers (SCLCs). Here, a genome-wide CRISPR/Cas9 LSD1 inhibitor resistance screen identifies the mRNA-binding protein ZFP36L1 as a gene repressed by LSD1 that when restored inhibits SCLC neuroendocrine differentiation.

    • Hsiao-Yun Chen
    • Yavuz T. Durmaz
    • Matthew G. Oser
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-22

  • Lineage plasticity is a source of intratumoural heterogeneity and enables tumour adaptation to an adverse tumour microenvironment, eventually leading to therapeutic resistance. The authors of this Review provide an overview of the impact of lineage plasticity on cancer progression and therapy resistance, with a focus on neuroendocrine transformation in lung and prostate tumours, and discuss emerging management strategies and open questions in the field.

    • Álvaro Quintanal-Villalonga
    • Joseph M. Chan
    • Charles M. Rudin
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 17, P: 360-371